Teri Loxam - 17 Sep 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Teri Loxam, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
17 Sep 2024
Net transactions value
-$584,856
Form type
4
Filing time
18 Sep 2024, 16:24:45 UTC
Previous filing
10 Jun 2024
Next filing
17 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $141,875 +6,250 +87% $22.70 13,425 17 Sep 2024 Direct
transaction PCVX Common Stock Sale $27,628 -241 -1.8% $114.64 13,184 17 Sep 2024 Direct F1, F2
transaction PCVX Common Stock Sale $166,634 -1,445 -11% $115.32 11,739 17 Sep 2024 Direct F1, F3
transaction PCVX Common Stock Sale $502,387 -4,308 -37% $116.62 7,431 17 Sep 2024 Direct F1, F4
transaction PCVX Common Stock Sale $30,083 -256 -3.4% $117.51 7,175 17 Sep 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -6,250 -33% $0.000000 12,500 17 Sep 2024 Common Stock 6,250 $22.70 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $113.93 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $115.04 to $115.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $116.25 to $117.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Option is fully vested and exercisable.